Please login to the form below

Not currently logged in

FDA sets 10 December date for Pfizer’s COVID-19 vaccine meeting

FDA newIndependent experts will discuss EUA submission for mRNA-based vaccine

Lilly links up with Precision BioSciences in genome editing deal

Eli Lilly new HQPrecision will receive an upfront cash payment of $100m

AZ’s COVID-19 vaccine demonstrates efficacy rate of up to 90%

AZ NEWAcross two dosing regimens, vaccine has average efficacy of 70%

UK could approve Pfizer’s COVID-19 vaccine this week

Coronavirus vaccineThe Telegraph reported the possible timeframe on Sunday

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

RegeneronDrug approved to treat high-risk patients with mild to moderate COVID-19

Lilly’s repurposed COVID-19 med baricitinib bags FDA emergency approval

Eli Lilly new HQDrug approved for emergency use in combination with Gilead's remdesivir

Pfizer, BioNTech to submit emergency use request for COVID-19 vaccine to FDA today

Pfizer BiontechShot could be available for high-risk populations in the US by middle of December

Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

NICE (National for Health and Clinical Excellence)Drug approved in combination with Merck's KGaA's Erbitux

Caroline GoslingQ&A: Caroline Gosling

PME interviews Rubica's Director of Culture & Engagement

Latest appointments

COVID-19 Updates and Daily News

Featured jobs


Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...